Navigation Links
Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
Date:4/28/2009

risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology MVA-BN(R) is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE(R).

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit http://www.bavarian-nordic.com


'/>"/>
SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Bavarian Nordic Publishes its Annual Results 2008
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Myriant Corporation, a global ... a distribution agreement with Azelis Group, a specialty ... bio-succinic acid in the Nordics, Benelux, France, Iberia, ... in the industrial and base chemicals markets. , ... a far-reaching chemical portfolio with extensive distribution networks ...
(Date:9/2/2014)... 2, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) ... Chief Executive Officer, will present at the Rodman & Renshaw ... New York on Tuesday, Sept. 9, 2014 at ... webcast of the presentation will be accessible by visiting the ... section. About Oncothyreon Oncothyreon ...
(Date:9/2/2014)... -- Spherix Incorporated (SPEX) -- an intellectual property development company committed to ... that the United States Patent & Trademark Office (USPTO) ... of August that are part of a standard essential ... are: , U.S.RE45,065 issued August 5, ... , U.S.RE45,095 issued August 26, 2014.  ...
(Date:9/1/2014)... The global oligonucleotide synthesis market is ... $1,070.7 million in 2014, growing at a CAGR ... oligonucleotide synthesis market is categorized on the basis ... geography. The synthesized oligonucleotides segment is expected to ... synthesis market during the forecast period, owing to ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5
... , , , SAN ... "DAS181 Inhibits H5N1 Influenza Lung Virus Infection of Human Lung ... Agents and Chemotherapy (AAC). , , ... clinical development for Influenza-Like Illness. Unlike neuraminidase inhibitors (e.g. Tamiflu ...
... , CAMBRIDGE, Mass., Aug. 25 Peptimmune, ... of a clinical trial to evaluate the safety, tolerability, ... Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel ... other autoimmune diseases. , , The ...
... Medicago Inc. (TSX-V: MDG) a biotechnology company focused ... on proprietary manufacturing technologies and Virus-Like Particles (VLPs), ... Health Canada to commence a Phase I human ... ("H5N1 vaccine"). Enrollment of volunteers is now underway. ...
Cached Biology Technology:NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 2NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 3NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 4Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 2Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 3Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 2Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 3
(Date:9/2/2014)... the last decade in Taiyuan, China, have substantially improved ... greater than 50% reduction in costs associated with loss ... to researchers at the Columbia Center for Children,s Environmental ... the Shanxi Medical University, the Center of Diseases Control ... School of Public Health. , The study is the ...
(Date:9/2/2014)... Konservat-Lagersttte of lithographic limestone is well known as ... from that area (for example, Archaeopteryx). Now, for ... in the French equivalent of these outcrops - ... oldest known water treader. , Despite the abundance ... fossils have been obtained from the Late Kimmeridgian ...
(Date:9/2/2014)... people take stress in stride; others are done in ... the molecular mechanisms of this so-called stress gap in ... that could lead researchers to better understand the development ... "Like people, each animal has unique experiences as it ... life experiences can alter the expression of genes, and ...
Breaking Biology News(10 mins):Clean air halves health costs in Chinese city 2Exceptionally well preserved insect fossils from the Rhône Valley 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3
... team of Fox Chase Cancer Center scientists led by ... mutation that keeps a mouse strain from developing white ... report by Kappes and his colleagues appears in the ... discovered the mice with this naturally occurring defect in ...
... simian virus 40 produces the Large T antigen which inactivates ... pRb. In a study published in the Journal of Biological ... the discovery of an additional target for T antigen--a protein ... chromosomal region that is deleted in up to 30% of ...
... demonstrated that a gel applied in the vagina provides ... the herpes simplex Virus. The study, presented at the ... first to show that a gel can retain anti-viral ... was funded by the National Institutes of Health (NIH) ...
Cached Biology News:Fox Chase Cancer Center scientists identify immune-system mutation 2New binding target for oncogenic viral protein 2Topical treatment shown to inhibit HIV and herpes simplex virus infection 2
... Osmometer for 10 L sample. Ideal for small volume applications, including pediatric, neonatal, geriatric, general adult, ... in less than 3 minutes after turn-on. ... ... ...
X-Gal (5-Bromo-4-Chloro-3-Indoyl-beta -D-Galactopyranoside)...
Human Jagged 2 Biotinylated Affinity Purified PAb...
Griess Reagent component for determination of nitrite in aqueous solutions....
Biology Products: